160 related articles for article (PubMed ID: 38202741)
1. In Silico and In Vivo Pharmacokinetic Evaluation of 84-B10, a Novel Drug Candidate against Acute Kidney Injury and Chronic Kidney Disease.
Su M; Liu X; Zhao Y; Zhu Y; Wu M; Liu K; Yang G; Liu W; Wang L
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202741
[TBL] [Abstract][Full Text] [Related]
2. A novel 3-phenylglutaric acid derivative (84-B10) alleviates cisplatin-induced acute kidney injury by inhibiting mitochondrial oxidative stress-mediated ferroptosis.
Fan J; Xu X; Li Y; Zhang L; Miao M; Niu Y; Zhang Y; Zhang A; Jia Z; Wu M
Free Radic Biol Med; 2023 Jan; 194():84-98. PubMed ID: 36403736
[TBL] [Abstract][Full Text] [Related]
3. In vitro-in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapolation to human.
Alsmadi MM; Alzughoul SB
Biopharm Drug Dispos; 2023 Jun; 44(3):221-244. PubMed ID: 36319070
[TBL] [Abstract][Full Text] [Related]
4. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy.
Hu MC; Shi M; Gillings N; Flores B; Takahashi M; Kuro-O M; Moe OW
Kidney Int; 2017 May; 91(5):1104-1114. PubMed ID: 28131398
[TBL] [Abstract][Full Text] [Related]
5. LONP1 targets HMGCS2 to protect mitochondrial function and attenuate chronic kidney disease.
Bai M; Wu M; Jiang M; He J; Deng X; Xu S; Fan J; Miao M; Wang T; Li Y; Yu X; Wang L; Zhang Y; Huang S; Yang L; Jia Z; Zhang A
EMBO Mol Med; 2023 Feb; 15(2):e16581. PubMed ID: 36629048
[TBL] [Abstract][Full Text] [Related]
6. The Role of Mitochondria in Acute Kidney Injury and Chronic Kidney Disease and Its Therapeutic Potential.
Zhang X; Agborbesong E; Li X
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681922
[TBL] [Abstract][Full Text] [Related]
7. Capillary rarefaction is more closely associated with CKD progression after cisplatin, rhabdomyolysis, and ischemia-reperfusion-induced AKI than renal fibrosis.
Menshikh A; Scarfe L; Delgado R; Finney C; Zhu Y; Yang H; de Caestecker MP
Am J Physiol Renal Physiol; 2019 Nov; 317(5):F1383-F1397. PubMed ID: 31509009
[TBL] [Abstract][Full Text] [Related]
8. Differential role of nicotinamide adenine dinucleotide deficiency in acute and chronic kidney disease.
Faivre A; Katsyuba E; Verissimo T; Lindenmeyer M; Rajaram RD; Naesens M; Heckenmeyer C; Mottis A; Feraille E; Cippà P; Cohen C; Longchamp A; Allagnat F; Rutkowski JM; Legouis D; Auwerx J; de Seigneux S
Nephrol Dial Transplant; 2021 Jan; 36(1):60-68. PubMed ID: 33099633
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine ameliorates cisplatin-induced renal senescence and renal interstitial fibrosis through sirtuin1 activation and p53 deacetylation.
Li C; Xie N; Li Y; Liu C; Hou FF; Wang J
Free Radic Biol Med; 2019 Jan; 130():512-527. PubMed ID: 30447351
[TBL] [Abstract][Full Text] [Related]
10. Subcellular trafficking of tubular MDM2 implicates in acute kidney injury to chronic kidney disease transition during multiple low-dose cisplatin exposure.
Su H; Ye C; Lei CT; Tang H; Zeng JY; Yi F; Zhang C
FASEB J; 2020 Jan; 34(1):1620-1636. PubMed ID: 31914692
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin nephrotoxicity as a model of chronic kidney disease.
Shi M; McMillan KL; Wu J; Gillings N; Flores B; Moe OW; Hu MC
Lab Invest; 2018 Aug; 98(8):1105-1121. PubMed ID: 29858580
[TBL] [Abstract][Full Text] [Related]
12. Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing.
Alasmari F; Alasmari MS; Muwainea HM; Alomar HA; Alasmari AF; Alsanea S; Alshamsan A; Rasool MF; Alqahtani F
Front Pharmacol; 2023; 14():1200828. PubMed ID: 37547336
[No Abstract] [Full Text] [Related]
13. Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors.
Sato K; Watanabe S; Ohtsubo A; Shoji S; Ishikawa D; Tanaka T; Nozaki K; Kondo R; Okajima M; Miura S; Tanaka J; Sakagami T; Koya T; Kagamu H; Yoshizawa H; Narita I
BMC Cancer; 2016 Mar; 16():222. PubMed ID: 26979596
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and AKI: an ongoing battle with new perspectives-a narrative review.
Volovat S; Apetrii M; Stefan A; Vlad C; Voroneanu L; Hogas M; Haisan A; Volovat C; Hogas S
Int Urol Nephrol; 2023 May; 55(5):1205-1209. PubMed ID: 36508071
[TBL] [Abstract][Full Text] [Related]
15. Curcumin prevents mitochondrial dynamics disturbances in early 5/6 nephrectomy: Relation to oxidative stress and mitochondrial bioenergetics.
Aparicio-Trejo OE; Tapia E; Molina-Jijón E; Medina-Campos ON; Macías-Ruvalcaba NA; León-Contreras JC; Hernández-Pando R; García-Arroyo FE; Cristóbal M; Sánchez-Lozada LG; Pedraza-Chaverri J
Biofactors; 2017 Mar; 43(2):293-310. PubMed ID: 27801955
[TBL] [Abstract][Full Text] [Related]
16. Post-operative acute kidney injury in patients with renal cell carcinoma is a potent risk factor for new-onset chronic kidney disease after radical nephrectomy.
Cho A; Lee JE; Kwon GY; Huh W; Lee HM; Kim YG; Kim DJ; Oh HY; Choi HY
Nephrol Dial Transplant; 2011 Nov; 26(11):3496-501. PubMed ID: 21406544
[TBL] [Abstract][Full Text] [Related]
17. Subclinical chronic kidney disease modifies the diagnosis of experimental acute kidney injury.
Succar L; Pianta TJ; Davidson T; Pickering JW; Endre ZH
Kidney Int; 2017 Sep; 92(3):680-692. PubMed ID: 28476556
[TBL] [Abstract][Full Text] [Related]
18. Renal Cell-Targeted Drug Delivery Strategy for Acute Kidney Injury and Chronic Kidney Disease: A Mini-Review.
Liu D; Du Y; Jin FY; Xu XL; Du YZ
Mol Pharm; 2021 Sep; 18(9):3206-3222. PubMed ID: 34337953
[TBL] [Abstract][Full Text] [Related]
19. Rodent models of AKI-CKD transition.
Fu Y; Tang C; Cai J; Chen G; Zhang D; Dong Z
Am J Physiol Renal Physiol; 2018 Oct; 315(4):F1098-F1106. PubMed ID: 29949392
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect and underlying mechanism of Shenkang injection against cisplatin-induced acute kidney injury in mice.
Su J; He T; You J; Cao J; Wang Q; Cao S; Mei Q; Zeng J; Liu L
J Ethnopharmacol; 2023 Jan; 301():115805. PubMed ID: 36216195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
